Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | HRAS G13V PIK3CA E545K |
Therapy | Tipifarnib |
Indication/Tumor Type | salivary gland carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
HRAS G13V PIK3CA E545K | salivary gland carcinoma | predicted - sensitive | Tipifarnib | Case Reports/Case Series | Actionable | In a clinical case study, Zarnestra (tipifarnib) treatment resulted in a partial response and progression-free survival lasting more than 5 months in a patient with androgen-receptor (AR)-positive salivary duct carcinoma harboring HRAS G13V and PIK3CA E545K (PMID: 37427101). | 37427101 |
PubMed Id | Reference Title | Details |
---|---|---|
(37427101) | Targeted treatment in a case series of AR+, HRAS/PIK3CA co-mutated salivary duct carcinoma. | Full reference... |